{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-028359","form_type":"8-K","ticker":"AIXC","cik":"0001460702","company_name":"AIxCrypto Holdings, Inc.","filed_at":"2024-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.119506+00:00","generated_at":"2026-05-31T19:37:13.198526+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Qualigen Therapeutics Advances $1.25 Million to Marizyme via Promissory Note at 18% Interest","bullets":["Qualigen advanced $1,250,000 to Marizyme, Inc. on July 15, 2024, under a demand promissory note dated July 12, 2024.","The note bears interest at 18% per annum and allows prepayment without premium or penalty.","The agreement is disclosed under Item 1.01 of Form 8-K filed July 18, 2024, signed by CEO Michael S. Poirier."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-028359","json":"https://secwatch.observer/filing/0001493152-24-028359.json","markdown":"https://secwatch.observer/filing/0001493152-24-028359.md","text":"https://secwatch.observer/filing/0001493152-24-028359.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1460702/000149315224028359/0001493152-24-028359-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1460702/000149315224028359/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T19:37:13.198526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}